Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes von Hallakou‐Bozec, Sophie, Vial, Guillaume, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Borel, Anne‐Laure, Fontaine, Eric, Moller, David E.

Volltext

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats von Hallakou‐Bozec, Sophie, Kergoat, Micheline, Moller, David E., Bolze, Sébastien

Volltext

Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy von Monternier, Pierre‐Axel, Singh, Jaspreet, Parasar, Parveen, Theurey, Pierre, DeWitt, Sheila, Jacques, Vincent, Klett, Eric, Kaur, Navtej, Nagaraja, Tavarekere N., Moller, David E., Hallakou‐Bozec, Sophie

Volltext

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action von Hallakou-Bozec, Sophie, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E

Volltext

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells von Vial, Guillaume, Lamarche, Frédéric, Cottet‐Rousselle, Cécile, Hallakou‐Bozec, Sophie, Borel, Anne‐Laure, Fontaine, Eric

Volltext

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis von Gluais‐Dagorn, Pascale, Foretz, Marc, Steinberg, Gregory R., Batchuluun, Battsetseg, Zawistowska‐Deniziak, Anna, Lambooij, Joost M., Guigas, Bruno, Carling, David, Monternier, Pierre‐Axel, Moller, David E., Bolze, Sebastien, Hallakou‐Bozec, Sophie

Volltext

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity von Theurey, Pierre, Thang, Carole, Pirags, Valdis, Mari, Andrea, Pacini, Giovanni, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Fouqueray, Pascale

Volltext

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin von Theurey, Pierre, Vial, Guillaume, Fontaine, Eric, Monternier, Pierre‐Axel, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Hallakou‐Bozec, Sophie

Volltext

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity von Jacques, Vincent, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Czarnik, Anthony W., Divakaruni, Ajit S., Fouqueray, Pascale, Murphy, Anne N., Van der Ploeg, Lex H.T., DeWitt, Sheila

Volltext

Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model von Vial, Guillaume, Chauvin, Marie-Agnès, Bendridi, Nadia, Durand, Annie, Meugnier, Emmanuelle, Madec, Anne-Marie, Bernoud-Hubac, Nathalie, Pais de Barros, Jean-Paul, Fontaine, Éric, Acquaviva, Cécile, Hallakou-Bozec, Sophie, Bolze, Sébastien, Vidal, Hubert, Rieusset, Jennifer

Volltext

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome von Lachaux, Marianne, Soulié, Matthieu, Hamzaoui, Mouad, Bailly, Anaëlle, Nicol, Lionel, Rémy‐Jouet, Isabelle, Renet, Sylvanie, Vendeville, Cathy, Gluais‐Dagorn, Pascale, Hallakou‐Bozec, Sophie, Monteil, Christelle, Richard, Vincent, Mulder, Paul

Volltext

Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents von Perry, Rachel J, Cardone, Rebecca L, Petersen, Max C, Zhang, Dongyan, Fouqueray, Pascale, Hallakou-Bozec, Sophie, Bolze, Sébastien, Shulman, Gerald I, Petersen, Kitt Falk, Kibbey, Richard G

Volltext

Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1) von Harrison, Stephen A., Thang, Carole, Bolze, Sébastien, Dewitt, Sheila, Hallakou-Bozec, Sophie, Dubourg, Julie, Bedossa, Pierre, Cusi, Kenneth, Ratziu, Vlad, Grouin, Jean-Marie, Moller, David E., Fouqueray, Pascale

Volltext

MO019: Preclinical Efficacy of Direct AMPK Activation with a Novel Small Molecule–PXL770–For the Treatment of Autosomal Dominant Polycystic Kidney Disease von Gluais Dagorn, Pascale, Buchholz, Bjoern, Bange, Hester, Blockken, Laura, Moller, David E, Hallakou-Bozec, Sophie

Volltext

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease von Dagorn, Pascale Gluais, Buchholz, Bjoern, Kraus, Andre, Batchuluun, Battsetseg, Bange, Hester, Blockken, Laura, Steinberg, Gregory R., Moller, David E., Hallakou-Bozec, Sophie

Volltext

386-P: Chronic Treatment with the Direct AMPK Activator PXL770 Improves Cardiac, Vascular, and Renal Function in Rodents with Diabetes-Related Cardiorenal Disease von STEPHAN, YOHAN, SOULIÉ, MATTHIEU, NICOL, LIONEL, GLUAIS-DAGORN, PASCALE, HALLAKOU-BOZEC, SOPHIE, MULDER, PAUL

Volltext

Validation of direct AMP kinase (AMPK) activation for treatment of X-linked Adrenoleukodystrophy von Monternier, Pierre-Axel, Singh, Jaspreet, Gluais, Pascale, Moller, David, Bozec, Sophie

Volltext

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy von Monternier, Pierre-Axel, Parasar, Parveen, Theurey, Pierre, Gluais Dagorn, Pascale, Kaur, Navtej, Nagaraja, Tavarekere N, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Singh, Jaspreet, Hallakou-Bozec, Sophie

Volltext

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled,... von Cusi, Kenneth, Alkhouri, Naim, Harrison, Stephen A, Fouqueray, Pascale, Moller, David E, Hallakou-Bozec, Sophie, Bolze, Sebastien, Grouin, Jean-Marie, Jeannin Megnien, Sophie, Dubourg, Julie, Ratziu, Vlad

Volltext

IMEGLIMIN PRESERVES BETA CELL FUNCTION AND MASS IN MALE ZUCKER DIABETIC FATTY RATS von Hallakou-Bozec, Sophie, Kergoat, Micheline, Bolze, Sébastien, Lebovitz, Harold E

Volltext